Evotec Strengthens its Ion Channel Capabilities to Support new Alliances
News Jun 30, 2009
Evotec AG has announced the expansion of its ion channel capabilities with the addition of ion channel focused libraries and additional electrophysiology screening platforms.
The libraries will be integrated into Evotec’s screening library, providing Evotec’s screening partners access to a high quality, diverse and highly relevant screening library for high-throughput screening collaborations, including the screening of ion channel targets.
Furthermore, Evotec has increased its considerable capability in ion channel screening through the addition of a Sophion Q-Patch electrophysiology platform as well as manual rigs equipped with Cellectricon’s Dynaflow® perfusion electrophysiology system.
This instrumentation will expand Evotec’s capabilities in ion channel screening which already includes an IonWorks® Quattro™ (Molecular Devices) for high-throughput electrophysiology, a PatchXpress® (Molecular Devices) and PatchLiner© (Nanion) systems for medium-throughput electrophysiology as well as two planar semi-automated Port-A-Patch® (Nanion) and numerous manual rigs.
This platform and know-how together with the screening library and Evotec’s medicinal chemistry expertise is accessible to Evotec’s alliance partners, providing a comprehensive approach for ion channel drug discovery.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE